Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$43.89|
|52 Week High||US$33.36|
|52 Week Low||US$51.86|
|1 Month Change||-10.06%|
|3 Month Change||13.09%|
|1 Year Change||19.82%|
|3 Year Change||-0.39%|
|5 Year Change||28.11%|
|Change since IPO||1,383.61%|
Recent News & Updates
Pfizer's 3CL Protease Inhibitor May Cut The Achilles' Heel Of COVID-19
Novel 3CL protease inhibitor under development. Pivot in vaccination strategy telegraphed in Fox interview. Hole in vaccination strategy creates a greater need for oral antivirals. Competition lurking but underfunded.
Even with Vaccine Success, Pfizer (NYSE:PFE) Returns are Lagging the Broad Market
There are but few corners of the Earth that the brand power of Pfizer Inc. (NYSE: PFE) didn't reach in recent times, as a pharmaceutical giant made the best out of one of the more peculiar moments in recent history. This article will examine the latest developments and look at the total shareholder returns stretching back the last 5 years.
|PFE||US Pharmaceuticals||US Market|
Return vs Industry: PFE exceeded the US Pharmaceuticals industry which returned 11% over the past year.
Return vs Market: PFE underperformed the US Market which returned 33.8% over the past year.
Stable Share Price: PFE is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.
About the Company
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.
Pfizer Fundamentals Summary
|PFE fundamental statistics|
Is PFE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PFE income statement (TTM)|
|Cost of Revenue||US$16.03b|
Last Reported Earnings
Jul 04, 2021
Next Earnings Date
|Earnings per share (EPS)||2.21|
|Net Profit Margin||22.20%|
How did PFE perform over the long term?See historical performance and comparison
3.6%Current Dividend Yield
Is Pfizer undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PFE ($43.89) is trading below our estimate of fair value ($94.3)
Significantly Below Fair Value: PFE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PFE is good value based on its PE Ratio (20x) compared to the US Pharmaceuticals industry average (22.9x).
PE vs Market: PFE is poor value based on its PE Ratio (20x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: PFE's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: PFE is overvalued based on its PB Ratio (3.5x) compared to the US Pharmaceuticals industry average (3.3x).
How is Pfizer forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PFE's earnings are forecast to decline over the next 3 years (-2.2% per year).
Earnings vs Market: PFE's earnings are forecast to decline over the next 3 years (-2.2% per year).
High Growth Earnings: PFE's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PFE's revenue is expected to decline over the next 3 years (-9.2% per year).
High Growth Revenue: PFE's revenue is forecast to decline over the next 3 years (-9.2% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PFE's Return on Equity is forecast to be high in 3 years time (21.2%)
How has Pfizer performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PFE has high quality earnings.
Growing Profit Margin: PFE's current net profit margins (22.2%) are higher than last year (19.1%).
Past Earnings Growth Analysis
Earnings Trend: PFE's earnings have declined by 2.9% per year over the past 5 years.
Accelerating Growth: PFE's earnings growth over the past year (86.3%) exceeds its 5-year average (-2.9% per year).
Earnings vs Industry: PFE earnings growth over the past year (86.3%) exceeded the Pharmaceuticals industry 17.5%.
Return on Equity
High ROE: PFE's Return on Equity (17.6%) is considered low.
How is Pfizer's financial position?
Financial Position Analysis
Short Term Liabilities: PFE's short term assets ($48.8B) exceed its short term liabilities ($35.7B).
Long Term Liabilities: PFE's short term assets ($48.8B) do not cover its long term liabilities ($63.9B).
Debt to Equity History and Analysis
Debt Level: PFE's debt to equity ratio (55.8%) is considered high.
Reducing Debt: PFE's debt to equity ratio has reduced from 70% to 55.8% over the past 5 years.
Debt Coverage: PFE's debt is well covered by operating cash flow (60%).
Interest Coverage: PFE's interest payments on its debt are well covered by EBIT (14.7x coverage).
What is Pfizer current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: PFE's dividend (3.55%) is higher than the bottom 25% of dividend payers in the US market (1.33%).
High Dividend: PFE's dividend (3.55%) is low compared to the top 25% of dividend payers in the US market (3.6%).
Stability and Growth of Payments
Stable Dividend: PFE's dividends per share have been stable in the past 10 years.
Growing Dividend: PFE's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (69.7%), PFE's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: PFE's dividends in 3 years are forecast to be well covered by earnings (50% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Albert Bourla (59 yo)
Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and has been its Executive Director since February 23, 2018. Dr. Bourla was Chief Operating Officer...
CEO Compensation Analysis
Compensation vs Market: Albert's total compensation ($USD21.03M) is above average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Albert's compensation has been consistent with company performance over the past year.
Experienced Management: PFE's management team is considered experienced (2.7 years average tenure).
Experienced Board: PFE's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PFE insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pfizer Inc.'s employee growth, exchange listings and data sources
- Name: Pfizer Inc.
- Ticker: PFE
- Exchange: NYSE
- Founded: 1849
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$246.078b
- Shares outstanding: 5.61b
- Website: https://www.pfizer.com
Number of Employees
- Pfizer Inc.
- 235 East 42nd Street
- New York
- New York
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/18 22:03|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.